Quantum-Si Incorporated Class A (QSI)

Quantum-Si's stock (QSI) has experienced volatility in the past six months. The stock price increased significantly over the last 12 months but had a negative year-to-date return. Key events include Q2 2025 earnings report with revenue below estimates, Q1 2025 earnings report with revenue increase, a $50 million capital raise, insider selling, varied analyst ratings, and the influence of market sentiment and "quantum hype."

Explicit information regarding strict seasonal demand patterns for Quantum-Si's products and services is not detailed in the available data. However, several factors have been identified that influence demand and revenue trends. The company's revenue can be variable in the near term due to the initial stages of commercialization and the mix of instrument versus consumable sales. NIH funding headwinds and related market uncertainties have impacted demand, particularly in the U.S. academic market. To mitigate such impacts and drive growth, Quantum-Si is strategically focusing on expanding its customer base in the biopharma segment and accelerating its international expansion.

Quantum-Si, Inc. is a biotechnology company focused on revolutionizing proteomics with its semiconductor chip-based technology. Founded in 2013 and headquartered in Branford, Connecticut, it operates in the life sciences sector, specifically in biotechnology and medical devices, with a focus on next-generation protein sequencing (NGPS). Its major products include the Platinum® NGPS instrument, the Platinum Pro NGPS instrument, Platinum Analysis Software, and a range of consumables. The company is also developing the Proteus™ platform, an advanced sequencing product.

Quantum-Si's headquarters are in Branford, Connecticut, USA. The company has expanded internationally with an Avantor distribution agreement in North America and a network of 15 partners across Western Europe, Eastern Europe, Asia, the Middle East, Africa, South America, and the South Pacific. Approximately 60% of its installed instrument base is located outside the United States.

Quantum-Si is in the early stages of commercialization and is building its brand through trade shows, conferences, and webinars. Customer feedback for the version 2 sequencing kit has been positive. The company's reputation has been affected by "quantum hype," with some investors mistakenly associating it with quantum computing, leading to stock price fluctuations.

The ownership structure of Quantum-Si (QSI) stock includes institutional, insider, and retail investors. Approximately 31.04% of the company's stock is owned by institutional investors. Individual investors hold a substantial 45.84% stake. Insiders own approximately 23.12% of the company's stock, with Jonathan M. Rothberg being the largest individual shareholder.